Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Andreas Hochhaus, Hagop M. Kantarjian et al.|Blood|2013Cited by 391
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Srinivas K. Tantravahi et al.|Cancer Cell|2014Cited by 366
A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaVaidehi Krishnan, S. Tiong Ong, Florian Schmidt et al.|Blood|2023Cited by 36
A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaVaidehi Krishnan, S. Tiong Ong, Florian Schmidt et al.|Blood|2022Cited by 15
Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling PathwaysWei Xiang, Charles Chuah|International Journal of Molecular Sciences|2024Cited by 1